摘要
目的探讨曲美他嗪联合美托洛尔对冠心病心力衰竭患者心功能的改善作用。方法选择我院2014年3月～2015年1月收治的冠心病心力衰竭患者102例为研究对象，以随机数字表法分组，观察组51例，对照组51例，两组患者均采取常规治疗方案，对照组加用美托洛尔治疗，观察组加美托洛尔联合曲美他嗪治疗。：对两组患者治疗后心功能进行观察。结果治疗前两组患者心功能各项指标无明显差异，治疗后均有改善，观察组治疗后心功能指标优于对照组，差异存在统计学意义（P〈0．05）；对照组不良反应发生率9．80％，对照组为11．76％，两组差异无统计学意义（P〉0．05）。结论曲美他嗪联合美托洛尔对冠心病心力衰竭进行治疗具有较好疗效，两者可起到协同作用，促进心功能改善。
Objective To study the trimetazidine joint metoprolol the improvement of heart function in patients with coronary heart disease heartfailure. Methods From March 2014 to January 2015, 102 patients with coronary heart disease, heart failure as the research object, by the method of random Numbers table group, 51 cases of observation group, control group in 51 cases, two groups of patients were treated with conventional scheme, the control group treated with metoprolol, observation group with metoprolol combined trimetazidine treatment, for the treatment of two groups of patients to look at the middle of the back function. Results No difference between the two groups of patients with cardiac function indicators before and after the treatment are improved, the middle of the back function index observation treatment group was better than control group, there are statistically significant difference （P 〈 0.05）, Control group 9.80% incidence of adverse reactions, the control group was 9.80%, the difference between the two groups has no statistical significance （P 〉 0.05）. Conclusion Trimetazidine combined metoprolol has good curative effect on coronary heart disease heart failure treatment, both can have synergy, improve heart function.
出处
《中国继续医学教育》
2015年第30期145-147,共3页
China Continuing Medical Education
关键词
曲美他嗪
美托洛尔
冠心病
心力衰竭
Trimetazidine, Metoprolol, Coronary heart disease, Heartfailure
